|Articles|July 1, 2010

Regulatory Roundup: FDA Provides Online Course on its Drug-Regulation Activities

The US Food and Drug Administration's website now features a free online 90-minute training program on the "Past, Present, and Future of FDA Human Drug Regulation."

The US Food and Drug Administration's website now features a free online 90-minute training program on the “Past, Present, and Future of FDA Human Drug Regulation.” The mini web-seminar provides an overview of the agency’s activities, starting with why FDA was established. The course includes a series of information slides, audio presentations, and brief polling questions. At the end of the session, users can take a test to receive a continuing education (CE) certificate or a certificate of completion (non-CE). The online course covers the steps required to develop and market a new drug (as well as OTC, generic, and fast-track drugs), the role of the Center for Drug Evaluation and Research, and the Office of Generic Drugs, patents and market exclusivity, compliance and postapproval monitoring, and recent FDA initiatives such as the Sentinel System, the Critical Path initiative, emergency relief, and harmonization.The goal is to help physicians, industry, patients, healthcare providers, and consumers better understand FDA and its activities.


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.